Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press2410.17650/2313-805X.2015.2.2.41-49REVIEW ARTICLESОБЗОРНЫЕ СТАТЬИTrabectedin – the DNA minor groove binderТрабектедин – лиганд узкой бороздки ДНКBelitskyG. A.БелицкийГеннадий Альтерович
Russian Federation

Research Institute of Carcinogenesis, 24 Kashirskoye Shosse, Moscow, 115478, Russia

Россия, 115478, Москва, Каширское шоссе, 24

belitsga@gmail.comKirsanovK. I.КирсановК. И.
Russian Federation

Research Institute of Carcinogenesis, 24 Kashirskoye Shosse, Moscow, 115478, Russia

Россия, 115478, Москва, Каширское шоссе, 24

LesovayaE. A.ЛесоваяЕ. А.
Russian Federation

Research Institute of Carcinogenesis, 24 Kashirskoye Shosse, Moscow, 115478, Russia

Россия, 115478, Москва, Каширское шоссе, 24

YakubovskayaM. G.ЯкубовскаяМ. Г.
Russian Federation

Research Institute of Carcinogenesis, 24 Kashirskoye Shosse, Moscow, 115478, Russia

Россия, 115478, Москва, Каширское шоссе, 24

N.N. Blokhin Russian Cancer Research CenterНИИ канцерогенеза ФГБНУ «РОНЦ им. Н. Н. Блохина»150520152241490306201503062015Copyright ©; 2015, Belitsky G.A., Kirsanov K.I., Lesovaya E.A., Yakubovskaya M.G.Copyright ©; 2015, Белицкий Г.А., Кирсанов К.И., Лесовая Е.А., Якубовская М.Г.2015Belitsky G.A., Kirsanov K.I., Lesovaya E.A., Yakubovskaya M.G.Белицкий Г.А., Кирсанов К.И., Лесовая Е.А., Якубовская М.Г.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/24

Trabectedin (ET-743, Yondelis) is an alkaloid that was originally isolated from the Caribbean Sea squirt, Ecteinascidia turbinata and is now produced synthetically. Its chemical structure consists in three fused tetrahydroisoquinoline rings. Two of them, A and B, binds covalently to guanine residues in the minor groove of the DNA double helix to bend the molecule toward the major groove and the third ring C protrudes from the DNA duplex, apparently allowing interactions with several nuclear proteins. Binding to the minor groove of DNA, trabectedin trigger a cascade of events that interfere with several transcription factors, DNA binding proteins, and DNA repair pathways in particular nucleotide excision repair. It acts both as a DNA-alkylating drug and topoisomerase poison. Trabectedin-DNA adduct traps the nucleotide excision repair proteins repairing the DNA damage in transcribing genes and induces DNA strand breaks. Cells deficient in homologous recombination pathway which repairs these double-strand breaks show increased sensitivity to trabectedin. The most sensitive of them were myxoid liposarcomas. Trabectedin is also effective in chemotherapy-experienced patients with advanced, recurrent liposarcoma or leiomyosarcoma as well as in women with ovarian cancer and breast cancer with BRCAness phenotype. Besides of tumor cells Trabectedin inhibits inflammatory cells by affecting directly monocytes and tumorassociated macrophages and indirectly by inhibiting production of inflammatory mediators, the cytokines and chemokines. It inhibits also the MDR-1 gene, which is responsible for the resistance of cancer cells to chemotherapeutic agents and strikes tumor angiogenesis.

trabectedinDNA minor grooveligandmalignant tumorchemotherapyDNA repairrecombinationmetabolismhepatotoxicityтрабектединузкая бороздка ДНКлигандзлокачественная опухольхимиотерапиярепарация ДНКрекомби- нацияметаболизмгепатотоксичностьРоссийский фонд фундаментальных исследований, Фонд некоммерческих программ Дмитрия Зимина «Династия»1. Pommier Y., Kohlhagen G., Bailly C. et al. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996;35(41):13303–9.Pommier Y., Kohlhagen G., Bailly C. et al. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996;35(41):13303–9.2. Zewail-Foote M., Hurley L.H. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999;42(14):2493–7.Zewail-Foote M., Hurley L.H. Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999;42(14):2493–7.3. David-Cordonnier M.H., Gajate C., Olmea O. et al. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem Biol 2005;12(11):1201–10.David-Cordonnier M.H., Gajate C., Olmea O. et al. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem Biol 2005;12(11):1201–10.4. Basmadjian C., Zhao Q., Bentouhami E. et al. Cancer wars: natural products strike back. Front Chem 2014;2:20.Basmadjian C., Zhao Q., Bentouhami E. et al. Cancer wars: natural products strike back. Front Chem 2014;2:20.5. D'Incalci M., Galmarini C.M. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010;9(8): 2157–63.D'Incalci M., Galmarini C.M. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010;9(8): 2157–63.6. M arco E., Garcia-Nieto R., Mendieta J. et al. A 3.(ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions. J Med Chem 2002;45(4):871–80.M arco E., Garcia-Nieto R., Mendieta J. et al. A 3.(ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions. J Med Chem 2002;45(4):871–80.7. Gu irouilh-Barbat J., Antony S., Pommier Y. Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition. Mol Cancer Ther 2009;8(7):2007–14.Gu irouilh-Barbat J., Antony S., Pommier Y. Zalypsis (PM00104) is a potent inducer of gamma-H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition. Mol Cancer Ther 2009;8(7):2007–14.8. Erb a E., Cavallaro E., Damia G. et al. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring. Oncol Res 2004;14(11–12): 579–87.Erb a E., Cavallaro E., Damia G. et al. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring. Oncol Res 2004;14(11–12): 579–87.9. Verme ir M., Hemeryck A., Cuyckens F. et al. In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping. Biochem Pharmacol 2009;77(10):1642–54.Verme ir M., Hemeryck A., Cuyckens F. et al. In vitro studies on the metabolism of trabectedin (YONDELIS) in monkey and man, including human CYP reaction phenotyping. Biochem Pharmacol 2009;77(10):1642–54.10. Beume r J.H., Rademaker-Lakhai J.M., Rosing H. et al. Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer. Cancer Chemother Pharmacol 2007; 59(6):825–37.Beume r J.H., Rademaker-Lakhai J.M., Rosing H. et al. Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer. Cancer Chemother Pharmacol 2007; 59(6):825–37.11. Reid J .M., Kuffel M.J., Ruben S.L. et al. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin Cancer Res 2002;8(9): 2952–62.Reid J .M., Kuffel M.J., Ruben S.L. et al. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clin Cancer Res 2002;8(9): 2952–62.12. Brandon E.F., Sparidans R.W., Guijt K.J. et al. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs 2006;24(1):3–14.Brandon E.F., Sparidans R.W., Guijt K.J. et al. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug. Invest New Drugs 2006;24(1):3–14.13. Brandon E.F., Meijerman I., Klijn J.S. et al. In vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction. Anticancer Drugs 2005;16(9):935–43.Brandon E.F., Meijerman I., Klijn J.S. et al. In vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction. Anticancer Drugs 2005;16(9):935–43.14. Machiels J.P., Staddon A., Herremans C. et al. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies. Cancer Chemother Pharmacol 2014;74(4):729–37.Machiels J.P., Staddon A., Herremans C. et al. Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies. Cancer Chemother Pharmacol 2014;74(4):729–37.15. Strippoli S., Lorisso V., Albano A., Guida M. Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin. BMC Complement Altern Med 2013;13:199.Strippoli S., Lorisso V., Albano A., Guida M. Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin. BMC Complement Altern Med 2013;13:199.16. Takebayash i Y., Pourquier P., Zimonjic D.B. et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7(8):961–6.Takebayash i Y., Pourquier P., Zimonjic D.B. et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7(8):961–6.17. Damia G., D 'Incalci M. Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer 2007;43(12):1791–801.Damia G., D 'Incalci M. Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer 2007;43(12):1791–801.18. Herrero A.B. , Martin-Castellanos C., Marco E. et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006;66(16):8155–62.Herrero A.B. , Martin-Castellanos C., Marco E. et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res 2006;66(16):8155–62.19. Горбунова В.А. Новые направления лекарственного лечения сарком мягких тканей. Вестник РОНЦ 2009;11:2–3. [Gorbunova V.A. New ways of drug therapy of soft tissues sarcomas. Vestnik RONC = Bulletin of RCRC (Russian Cancer Research Center) 2009;11:2–3. (In Russ.)].Горбунова В.А. Новые направления лекарственного лечения сарком мягких тканей. Вестник РОНЦ 2009;11:2–3. [Gorbunova V.A. New ways of drug therapy of soft tissues sarcomas. Vestnik RONC = Bulletin of RCRC (Russian Cancer Research Center) 2009;11:2–3. (In Russ.)].20. Olofsson A., Wi llen H., Goransson M. et al. Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas. Int J Oncol 2004;25(5): 1349–55.Olofsson A., Wi llen H., Goransson M. et al. Abnormal expression of cell cycle regulators in FUS-CHOP carrying liposarcomas. Int J Oncol 2004;25(5): 1349–55.21. Forni C., Minuzz o M., Virdis E. et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 2009;8(2):449–57.Forni C., Minuzz o M., Virdis E. et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 2009;8(2):449–57.22. Charytonowicz E., Terry M., Coakley K. et al. PPARgamma agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. J Clin Invest 2012;122(3): 886–98.Charytonowicz E., Terry M., Coakley K. et al. PPARgamma agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. J Clin Invest 2012;122(3): 886–98.23. Di Giandomenico S. , Frapolli R., Bello E. et al. Mode of action of trabectedin in myxoid liposarcomas. Oncogene 2014;33(44):5201–10.Di Giandomenico S. , Frapolli R., Bello E. et al. Mode of action of trabectedin in myxoid liposarcomas. Oncogene 2014;33(44):5201–10.24. Grohar P.J., Griffi n L.B., Yeung C. et al. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia 2011;13(2):145–53.Grohar P.J., Griffi n L.B., Yeung C. et al. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia 2011;13(2):145–53.25. Peto J., Collins N., Barfoot R. et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999;91(11): 943–9.Peto J., Collins N., Barfoot R. et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999;91(11): 943–9.26. Turner N., Tutt A., A shworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4(10):814–9.Turner N., Tutt A., A shworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4(10):814–9.27. Delaloge S., Wolp-Dini z R., Byrski T. et al. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study. Ann Oncol 2014;25(6):1152–8.Delaloge S., Wolp-Dini z R., Byrski T. et al. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study. Ann Oncol 2014;25(6):1152–8.28. Massuti B., Cobo M., Ca mps C. et al. Trabectedin in patients with advanced nonsmall-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. Lung Cancer 2012;76(3):354–61.Massuti B., Cobo M., Ca mps C. et al. Trabectedin in patients with advanced nonsmall-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. Lung Cancer 2012;76(3):354–61.29. Monk B.J., Ghatage P., P arekh T. et al. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 studydagger. Ann Oncol 2015;26(5):914–20.Monk B.J., Ghatage P., P arekh T. et al. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 studydagger. Ann Oncol 2015;26(5):914–20.30. Guirouilh-Barbat J., Zhan g Y.W., Pommier Y. Induction of glutathionedependent DNA double-strand breaks by the novel anticancer drug brostallicin. Mol Cancer Ther 2009;8(7):1985–94.Guirouilh-Barbat J., Zhan g Y.W., Pommier Y. Induction of glutathionedependent DNA double-strand breaks by the novel anticancer drug brostallicin. Mol Cancer Ther 2009;8(7):1985–94.31. Casado J.A., Rio P., Marco E. et al. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther 2008;7(5):1309–18.Casado J.A., Rio P., Marco E. et al. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther 2008;7(5):1309–18.32. Chang M., Raimondi S.C., Ra vindranath Y. et al. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821. Leukemia 2000;14(7):1201–7.Chang M., Raimondi S.C., Ra vindranath Y. et al. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821. Leukemia 2000;14(7):1201–7.33. Port M., Böttcher M. Thol F. et al. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. Ann Hematol 2014;93(8):1279–86.Port M., Böttcher M. Thol F. et al. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. Ann Hematol 2014;93(8):1279–86.34. Moneo V., Serelde B.G., Fomin aya J. et al. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem 2007;100(2):339–48.Moneo V., Serelde B.G., Fomin aya J. et al. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem 2007;100(2):339–48.35. Jin S., Gorfajn B., Faircloth G., Scotto K.W. Ecteinascidin 743, a transcriptiontargeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 2000;97(12):6775–9.Jin S., Gorfajn B., Faircloth G., Scotto K.W. Ecteinascidin 743, a transcriptiontargeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 2000;97(12):6775–9.36. Ganjoo K.N., Patel S.R. Trabect edin: an anticancer drug from the sea. Expert Opin Pharmacother 2009;10(16):2735–43.Ganjoo K.N., Patel S.R. Trabect edin: an anticancer drug from the sea. Expert Opin Pharmacother 2009;10(16):2735–43.37. Fusco A., Fedele M. Roles of HMG A proteins in cancer. Nat Rev Cancer 2007;7(12):899–910.Fusco A., Fedele M. Roles of HMG A proteins in cancer. Nat Rev Cancer 2007;7(12):899–910.38. D'Angelo D., Borbone E., Palmieri D. et al. The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin. Eur J Cancer 2013;49(5):1142–51.D'Angelo D., Borbone E., Palmieri D. et al. The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin. Eur J Cancer 2013;49(5):1142–51.39. Pommier Y. DNA topoisomerase I inh ibitors: chemistry, biology, and interfacial inhibition. Chem Rev 2009;109(7):2894–902.Pommier Y. DNA topoisomerase I inh ibitors: chemistry, biology, and interfacial inhibition. Chem Rev 2009;109(7):2894–902.40. Martinez E.J., Corey E.J., Owa T. A ntitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650. Chem Biol 2001;8(12):1151–60.Martinez E.J., Corey E.J., Owa T. A ntitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650. Chem Biol 2001;8(12):1151–60.41. Tavecchio M., Simone M., Erba E. et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 2008;44(4):609–18.Tavecchio M., Simone M., Erba E. et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 2008;44(4):609–18.42. Garcia M.J., Saucedo-Cuevas L.P., Mun oz-Repeto I. et al. Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response. Mol Cancer Ther 2013;12(4):530–41.Garcia M.J., Saucedo-Cuevas L.P., Mun oz-Repeto I. et al. Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response. Mol Cancer Ther 2013;12(4):530–41.43. Soares D.G., Escarqueil A.E., Poindess ous V. et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci USA 2007;104(32): 13062–7.Soares D.G., Escarqueil A.E., Poindess ous V. et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci USA 2007;104(32): 13062–7.44. Uboldi S., Bemasconi S., Romano M. et a l. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents. Int J Cancer 2012;131(1):59–69.Uboldi S., Bemasconi S., Romano M. et a l. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents. Int J Cancer 2012;131(1):59–69.45. Donald S., Verschoyle R.D., Edwards R. et al. Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (ET-743) in the female rat. Cancer Res 2002;62(15): 4256–62.Donald S., Verschoyle R.D., Edwards R. et al. Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (ET-743) in the female rat. Cancer Res 2002;62(15): 4256–62.46. van Waterschoot R.A., Eman R.M., Wagenaar E. et al. ABCC2, ABCC3, and ABCB1, but not CYP3A, protect against trabectedin-mediated hepatotoxicity. Clin Cancer Res 2009;15(24):7616–23.van Waterschoot R.A., Eman R.M., Wagenaar E. et al. ABCC2, ABCC3, and ABCB1, but not CYP3A, protect against trabectedin-mediated hepatotoxicity. Clin Cancer Res 2009;15(24):7616–23.47. Laurenty A.P., Thomas F., Chatelut E. et a l. Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case report. Pharmacogenomics 2013;14(12):1389–96.Laurenty A.P., Thomas F., Chatelut E. et a l. Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case report. Pharmacogenomics 2013;14(12):1389–96.48. Donald S., Verschoyle R.D., Greaves P. et a l. Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro. Cancer Chemother Pharmacol 2004;53(4):305–12.Donald S., Verschoyle R.D., Greaves P. et a l. Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro. Cancer Chemother Pharmacol 2004;53(4):305–12.49. Donald S., Verschoyle R.D., Greaves P. et al . Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Res 2003;63(18):5902–8.Donald S., Verschoyle R.D., Greaves P. et al . Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Res 2003;63(18):5902–8.50. Lee J.K., Leslie E.M., ZamekGliszczynski M.J ., Brouwer K.L. Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity. Toxicol Appl Pharmacol 2008;228(1): 17–23.Lee J.K., Leslie E.M., ZamekGliszczynski M.J ., Brouwer K.L. Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicity. Toxicol Appl Pharmacol 2008;228(1): 17–23.51. Minuzzo M., Marchini S., Broqqini M. et al. In terference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 2000;97(12):6780–4.Minuzzo M., Marchini S., Broqqini M. et al. In terference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 2000;97(12):6780–4.52. Leibelt D.A., Hedstrom O.R., Fischer K.A. et al . Evaluation of chronic dietary exposure to indole-3-carbinol and absorption-enhanced 3,3'-diindolylmethane in sprague-dawley rats. Toxicol Sci 2003;74(1):10–21.Leibelt D.A., Hedstrom O.R., Fischer K.A. et al . Evaluation of chronic dietary exposure to indole-3-carbinol and absorption-enhanced 3,3'-diindolylmethane in sprague-dawley rats. Toxicol Sci 2003;74(1):10–21.53. Donald S., Verschoyle R.D., Greaves P. et al. Di etary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectеdin) without compromising efficacy in a rat mammary carcinoma. Int J Cancer 2004;111(6):961–7.Donald S., Verschoyle R.D., Greaves P. et al. Di etary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectеdin) without compromising efficacy in a rat mammary carcinoma. Int J Cancer 2004;111(6):961–7.54. Grosso F., Dileo P., Sanfilippo R. et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 2006;42(10):1484–90.Grosso F., Dileo P., Sanfilippo R. et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 2006;42(10):1484–90.55. Paz-Ares L., López-Pousa A., Poveda A. et al. Trab ectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs 2012;30(2):729–40.Paz-Ares L., López-Pousa A., Poveda A. et al. Trab ectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs 2012;30(2):729–40.56. Murray P.J., Wynn T.A. Protective and pathogenic fu nctions of macrophage subsets. Nat Rev Immunol 2011;11(11):723–37.Murray P.J., Wynn T.A. Protective and pathogenic fu nctions of macrophage subsets. Nat Rev Immunol 2011;11(11):723–37.57. Allavena P., Mantovani A. Immunology in the clinic r eview series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 2012;167(2):195–205.Allavena P., Mantovani A. Immunology in the clinic r eview series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol 2012;167(2):195–205.58. Qian B.Z., Li J., Zhang H. et al. CCL2 recruits infla mmatory monocytes to facilitate breast-tumour metastasis. Nature 2011;475(7355):222–5.Qian B.Z., Li J., Zhang H. et al. CCL2 recruits infla mmatory monocytes to facilitate breast-tumour metastasis. Nature 2011;475(7355):222–5.59. Germano G., Frapolli R., Simone M. et al. Antitumor an d anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 2010;70(6):2235–44.Germano G., Frapolli R., Simone M. et al. Antitumor an d anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 2010;70(6):2235–44.60. Germano G., Frapolli R., Belqiovine C. et al. Role of m acrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013;23(2):249–62.Germano G., Frapolli R., Belqiovine C. et al. Role of m acrophage targeting in the antitumor activity of trabectedin. Cancer Cell 2013;23(2):249–62.61. Allavena P., Germano G., Belgiovine C. et al. Trabectedi n: A drug from the sea that strikes tumor-associated macrophages. Oncoimmunology 2013;2(6):e24614.Allavena P., Germano G., Belgiovine C. et al. Trabectedi n: A drug from the sea that strikes tumor-associated macrophages. Oncoimmunology 2013;2(6):e24614.62. Stevens E.V., Nishizuka S., Antony S. et al. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther 2008;7(1):10–8.Stevens E.V., Nishizuka S., Antony S. et al. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol Cancer Ther 2008;7(1):10–8.63. Lopez-Guerrero J.A., Romero I., Poveda A. Trabectedin the rapy as an emerging treatment strategy for recurrent platinumsensitive ovarian cancer. Chin J Cancer 2015;34(1):41–9.Lopez-Guerrero J.A., Romero I., Poveda A. Trabectedin the rapy as an emerging treatment strategy for recurrent platinumsensitive ovarian cancer. Chin J Cancer 2015;34(1):41–9.64. Pautier P., Floques A., Chevreau C. et al. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol 2015;16(4):457–64.Pautier P., Floques A., Chevreau C. et al. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. Lancet Oncol 2015;16(4):457–64.65. Kawano M., Mabuchi S., Kishimoto T. et al. Combination trea tment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells. Int J Gynecol Cancer 2014;24(5): 829–37.Kawano M., Mabuchi S., Kishimoto T. et al. Combination trea tment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells. Int J Gynecol Cancer 2014;24(5): 829–37.66. Riccardi A., Meco D., Ubezio P. et al. Combination of trabec tedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft. Anticancer Drugs 2005;16(8):811–5.Riccardi A., Meco D., Ubezio P. et al. Combination of trabec tedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft. Anticancer Drugs 2005;16(8):811–5.67. Stephens B.J., Han H., Gokhale V., Von Hoff D.D. PRL phosphat ases as potential molecular targets in cancer. Mol Cancer Ther 2005;4(11):1653–61.Stephens B.J., Han H., Gokhale V., Von Hoff D.D. PRL phosphat ases as potential molecular targets in cancer. Mol Cancer Ther 2005;4(11):1653–61.68. Cai X., Gray P.J. Jr, Von Hoff D.D. DNA minor groove binders: back in the groove. Cancer Treat Rev 2009;35(5):437–50.Cai X., Gray P.J. Jr, Von Hoff D.D. DNA minor groove binders: back in the groove. Cancer Treat Rev 2009;35(5):437–50.69. Coward J.I., Middleton K., Murphy F. New perspectives on target ed therapy in ovarian cancer. Int J Womens Health 2015;7:189–203.Coward J.I., Middleton K., Murphy F. New perspectives on target ed therapy in ovarian cancer. Int J Womens Health 2015;7:189–203.70. Collins I.M., Thomas D.M. Novel approaches to treatment of leiom yosarcomas. Curr Oncol Rep 2011;13(4):316–22.Collins I.M., Thomas D.M. Novel approaches to treatment of leiom yosarcomas. Curr Oncol Rep 2011;13(4):316–22.71. Kirsanov K.I., Kotova E., Makhov P. et al. Minor grove binding ligands disrupt PARP-1 activation pathways. Oncotarget 2014;5(2):428–37.Kirsanov K.I., Kotova E., Makhov P. et al. Minor grove binding ligands disrupt PARP-1 activation pathways. Oncotarget 2014;5(2):428–37.